AU2020334489C1 - Salt and crystal form of compound having agonistic activity to S1P5 receptor - Google Patents
Salt and crystal form of compound having agonistic activity to S1P5 receptorInfo
- Publication number
- AU2020334489C1 AU2020334489C1 AU2020334489A AU2020334489A AU2020334489C1 AU 2020334489 C1 AU2020334489 C1 AU 2020334489C1 AU 2020334489 A AU2020334489 A AU 2020334489A AU 2020334489 A AU2020334489 A AU 2020334489A AU 2020334489 C1 AU2020334489 C1 AU 2020334489C1
- Authority
- AU
- Australia
- Prior art keywords
- crystal
- diffraction
- powder
- methyl
- ray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889091P | 2019-08-20 | 2019-08-20 | |
| US62/889,091 | 2019-08-20 | ||
| PCT/JP2020/031326 WO2021033729A1 (ja) | 2019-08-20 | 2020-08-19 | Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2020334489A1 AU2020334489A1 (en) | 2022-03-03 |
| AU2020334489B2 AU2020334489B2 (en) | 2025-10-30 |
| AU2020334489C1 true AU2020334489C1 (en) | 2026-03-26 |
| AU2020334489C8 AU2020334489C8 (en) | 2026-05-07 |
Family
ID=
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019163917A1 (ja) * | 2018-02-22 | 2019-08-29 | 小野薬品工業株式会社 | Ｓ１ｐ５受容体作動活性を有する化合物 |
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019163917A1 (ja) * | 2018-02-22 | 2019-08-29 | 小野薬品工業株式会社 | Ｓ１ｐ５受容体作動活性を有する化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI859303B (zh) | 2024-10-21 |
| TW202114984A (zh) | 2021-04-16 |
| MY207001A (en) | 2025-01-23 |
| EP4019496A4 (en) | 2023-01-11 |
| CN114302873A (zh) | 2022-04-08 |
| US20220289675A1 (en) | 2022-09-15 |
| EP4019496A1 (en) | 2022-06-29 |
| JP7409383B2 (ja) | 2024-01-09 |
| JPWO2021033729A1 (https=) | 2021-02-25 |
| WO2021033729A1 (ja) | 2021-02-25 |
| ES2983098T3 (es) | 2024-10-22 |
| US12459890B2 (en) | 2025-11-04 |
| MX2022001820A (es) | 2022-03-17 |
| KR20220050886A (ko) | 2022-04-25 |
| AU2020334489A1 (en) | 2022-03-03 |
| BR112022002632A2 (pt) | 2022-05-03 |
| KR102930707B1 (ko) | 2026-02-24 |
| AU2020334489B2 (en) | 2025-10-30 |
| IL290432A (en) | 2022-04-01 |
| PH12022550319A1 (en) | 2022-12-19 |
| EP4019496B1 (en) | 2024-06-05 |
| CA3150303A1 (en) | 2021-02-25 |
| NZ785003A (en) | 2024-09-27 |
| ZA202201784B (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12459890B2 (en) | Salt and crystal form of compound having agonistic activity to S1P5 receptor | |
| DE10311065A1 (de) | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung | |
| US12049445B2 (en) | Compounds having S1P5 receptor agonistic activity | |
| EP3339307A1 (en) | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions | |
| US6919342B2 (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| KR20180085814A (ko) | 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법 | |
| AU2020334489C8 (en) | Salt and crystal form of compound having agonistic activity to S1P5 receptor | |
| US20230293539A1 (en) | Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof | |
| JP2003524595A (ja) | 薬 剤 | |
| US20060194811A1 (en) | Pyrimidine derivatives | |
| DE69315307T2 (de) | Chimuclidine Derivate als Squalen synthetase Inhibitoren | |
| JP2011502971A (ja) | ドーパミンｄ３受容体の調節に応答する障害を治療するための１，２，４−トリアジン−３，５−ジオン化合物 | |
| RU2833357C2 (ru) | Соль и кристаллическая форма соединения, обладающего агонистической активностью по отношению к рецептору s1p5 | |
| HK40069904A (en) | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
| US20230024991A1 (en) | Prodrugs of acyl carnitines | |
| JP5680416B2 (ja) | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なベンゼンスルホンアミド化合物 | |
| JP2020502081A (ja) | Ｔｎｆ活性のモジュレーターとしての置換ベンゾイミダゾール誘導体 | |
| BR112020017036B1 (pt) | Compostos com atividade agonista do receptor esfingosina-1- fosfato de tipo 5 (s1p5), composição farmacêutica que compreende os mesmos e uso dos ditos compostos para prevenir e/ou tratar uma doença mediada por s1p5 | |
| HK40036181A (en) | Compound having s1p5 receptor agonist activity | |
| CZ324199A3 (cs) | Léčivo k zabránění růstu solidního tumoru u člověka a způsob jeho výroby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 DEC 2025 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED |
|
| FGA | Letters patent sealed or granted (standard patent) |